analysis for NCT00251719 [clinicaltrials_resource:NCT00251719/analysis/53ce21ebef8bc01b54941ac03c1054f2]
analysis [clinicaltrials_vocabulary:analysis]
analysis for NCT00251719 [clinicaltrials_resource:NCT00251719/analysis/53ce21ebef8bc01b54941ac03c1054f2]
Bio2RDF identifier
NCT00251719/analysis/53ce21ebef8bc01b54941ac03c1054f2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... ce21ebef8bc01b54941ac03c1054f2
method [clinicaltrials_vocabulary:method]
non inferiority [clinicaltrials_vocabulary:non-inferiority]
p value [clinicaltrials_vocabulary:p-value]
1.1699999868869779e-1
p value desc [clinicaltrials_vocabulary:p-value-desc]
Unadjusted p-value is presente ...... oprazole dose to lansoprazole.
identifier
clinicaltrials_resource:NCT00251719/analysis/53ce21ebef8bc01b54941ac03c1054f2
title
analysis for NCT00251719
@en
type
label
analysis for NCT00251719 [clin ...... e21ebef8bc01b54941ac03c1054f2]
@en